Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2025)

Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

Qiagen Nv (NYSE:QGEN) is the #1 top diagnostic & research stock out of 57 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: B, Growth: B, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: C.

Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 25, which is -1 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates QGEN as a "A".

QGEN passed 10 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock return 19.12% over the past year, overperforming other diagnostic & research stocks by 33 percentage points.

Qiagen Nv has an average 1 year price target of $49.40, an upside of 2.19% from Qiagen Nv's current stock price of $48.34.

Qiagen Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Qiagen Nv, 40% have issued a Strong Buy rating, 0% have issued a Buy, 60% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Fonar (NASDAQ:FONR) is the #2 top diagnostic & research stock out of 57 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Fonar (NASDAQ:FONR) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Fonar (NASDAQ:FONR) has a Due Diligence Score of 39, which is 13 points higher than the diagnostic & research industry average of 26.

FONR passed 11 out of 33 due diligence checks and has average fundamentals. Fonar has seen its stock lose -2.83% over the past year, overperforming other diagnostic & research stocks by 11 percentage points.

Illumina (NASDAQ:ILMN) is the #3 top diagnostic & research stock out of 57 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: C, Growth: A, Momentum: D, Sentiment: C, Safety: B, Financials: B, and AI: C.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 20, which is -6 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates ILMN as a "B".

ILMN passed 6 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -4.26% over the past year, overperforming other diagnostic & research stocks by 10 percentage points.

Illumina has an average 1 year price target of $106.00, an upside of 5.16% from Illumina's current stock price of $100.80.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.3%, which is 1 percentage points higher than the diagnostic & research industry average of 0.57%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.82%, which is the same as the diagnostic & research industry average of 0.57%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 33% indicates that its dividend yield is sustainable for the long-term.

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.4%, which is the same as the diagnostic & research industry average of 0.57%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 23.8% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were up 0.14% in the last day, and up 1.9% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 42 points higher than the diagnostic & research industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -52.8% in the past year. It has underperformed other stocks in the diagnostic & research industry by -39 percentage points.

Thermo Fisher Scientific (NYSE:TMO) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Thermo Fisher Scientific has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Thermo Fisher Scientific's stock has dropped -19.84% in the past year. It has underperformed other stocks in the diagnostic & research industry by -6 percentage points.

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 56 points higher than the diagnostic & research industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -2.83% in the past year. It has overperformed other stocks in the diagnostic & research industry by 11 percentage points.

50% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 12.66% over the next year.

4.76% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 14.29% of diagnostic & research stocks are rated B (Buy), 66.67% are rated C (Hold), 14.29% are rated D (Sell), and 0% are rated F (Strong Sell).